BeiGene Announces Closing of Its Initial Public Offering
February 08, 2016 16:30 ET
|
BeiGene Ltd.
BEIJING, Feb. 08, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (“BeiGene” or “the Company”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological...
BeiGene Announces Pricing of Its Initial Public Offering
February 02, 2016 21:30 ET
|
BeiGene Ltd.
BEIJING, Feb. 2, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. ("BeiGene" or "the Company"), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs...
U.S. IND Becomes Active for BGB-A317, an Anti-PD-1 Monoclonal Antibody
January 08, 2016 13:06 ET
|
BeiGene Ltd.
BEIJING, Jan. 08, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of...
BeiGene Presents Clinical Data for BTK Inhibitor BGB-3111 at 57th ASH Annual Meeting
December 07, 2015 18:00 ET
|
BeiGene Ltd.
BEIJING, Dec. 7, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Receives 2015 R&D Achievement of Year at BayHelix China Pharmaceutical Awards
November 17, 2015 08:00 ET
|
BeiGene Ltd.
BEIJING, Nov. 17, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Appoints Dr. Zhengming Du as Senior Vice President, Head of Chemistry and Manufacturing Controls
November 09, 2015 08:00 ET
|
BeiGene Ltd.
BEIJING, Nov. 9, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Announces Appointment of Dr. RuiRong Yuan as Chief Medical Officer and President of Global Clinical Development
November 02, 2015 08:00 ET
|
BeiGene Ltd.
BEIJING, Nov. 2, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Announces Abstracts to be Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 28, 2015 12:11 ET
|
BeiGene Ltd.
BEIJING, Oct. 28, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Doses First Patient in China With BGB-283 for Solid Tumors
October 12, 2015 10:47 ET
|
BeiGene Ltd.
BEIJING, Oct. 12, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Appoints Changzhen Wu as Head of Manufacturing Operations
September 30, 2015 08:00 ET
|
BeiGene Ltd.
BEIJING, Sept. 30, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...